




RealRate

PHARMACEUTICAL 2020

Bellerophon Therapeutics Inc.
Rank 282 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2020

Bellerophon Therapeutics Inc. Rank 282 of 362

The relative strengths and weaknesses of Bellerophon Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bellerophon Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 180% points. The greatest weakness of Bellerophon Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 221% points.

The company's Economic Capital Ratio, given in the ranking table, is -442%, being 139% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	10,382
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,584
Liabilities, Non-Current	1,659
Other Assets	2,410
Other Compr. Net Income	0
Other Expenses	-3,783
Other Liabilities	274
Other Net Income	397
Property and Equipment	316
Research and Development	11,032
Revenues	0
Selling, General and Administrative Expense	6,441

Output Variable	Value in 1000 USD
Assets	13,108
Liabilities	9,517
Expenses	13,690
Stockholders Equity	3,591
Net Income	-13,293
Comprehensive Net Income	-13,293
Economic Capital Ratio	-442%

